RESTING: Study of Enterra Programming With Nocturnal Cycling in Gastroparetics
Study Details
Study Description
Brief Summary
The purpose of this research study is to evaluate if different Enterra™ device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.
Participants in this study with existing Enterra™ devices will be randomly assigned to one of three programming methods that will be active during sleep. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits.
Participants will be involved in the study for up to six months after treatment assignment.
Programming parameters in the study are within currently approved labeling.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Control Sleep Cycle Baseline device programming parameters will be used during study participation. No modification to Enterra™ device programming will be in effect during waking or sleeping hours. |
Device: Enterra™ Therapy System
The Enterra™ Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Other Names:
|
| Experimental: Arm 1 Sleep Cycle Device programming parameters participants have at enrollment will be used during waking hours. During sleeping hours, the Enterra™ device will cycle through modified programming over the course of 6 hours. Each hour, the Enterra™ device will deliver 30 minutes of reduced stimulation, followed by 30 minutes of waking hours stimulation. At the end of the 6-hour sleep cycle, the Enterra™ device will return to waking hours programming. |
Device: Enterra™ Therapy System
The Enterra™ Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Other Names:
|
| Experimental: Arm 2 Sleep Cycle Device programming parameters participants have at enrollment will be used during waking hours. During sleeping hours, the Enterra™ device will cycle through modified programming over the course of 8 hours. Each hour, the Enterra™ device will deliver 45 minutes of reduced stimulation, followed by 15 minutes of waking hours stimulation. At the end of the 8-hour sleep cycle, the Enterra™ device will return to waking hours programming. |
Device: Enterra™ Therapy System
The Enterra™ Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percent Change in Weekly Vomiting Frequency by GCSI-DD [3 Months, 6 Months]
Less than a 50% increase in GCSI-DD weekly vomiting frequency from baseline
- Scoring Change in Nausea Severity by GCSI-DD [3 Months, 6 Months]
Less than a 1-point increase in GCSI-DD nausea severity from baseline
Secondary Outcome Measures
- Mean Change from Baseline in GCSI-DD Total Symptom Score [3 Months, 6 Months]
Change in GCSI-DD Total Symptom Score from baseline
- Mean Change from Baseline in GCSI-DD Nausea Severity [3 Months, 6 Months]
Change in GCSI-DD nausea severity from baseline
- Mean Change from Baseline in GCSI-DD Weekly Vomiting Frequency [3 Months, 6 Months]
Change in GCSI-DD weekly vomiting frequency from baseline
- Mean Change from Baseline in PAGI-QoL Scores [3 Months, 6 Months]
Change in PAGI-QoL from baseline
- Mean Change from Baseline in Quality of Sleep Scores [3 Months, 6 Months]
Change in Quality of Sleep from baseline
Eligibility Criteria
Criteria
In order to be eligible to participate in this study, a participant must meet all of the following criteria:
-
Completed informed consent process with signed and dated informed consent form;
-
Stated willingness to comply with all study procedures and availability for the duration of the study;
-
Male or female, aged ≥18 or ≤70 at time of informed consent;
-
Currently implanted with the Enterra™ Therapy System (Enterra™ II 37800 neurostimulator);
-
High GES output defined as remaining pulse generator expected life of > 9 months from enrollment and less than 4 years from the time of implant;
-
Stable gastroparesis symptoms, in the opinion of the investigator;
-
On stable medical therapy for gastroparesis symptoms;
-
On stable supplemental nutritional support during the month prior to enrollment.
A participant who meets any of the following criteria will be excluded from participation in this study:
-
Post-surgical gastroparesis (e.g., fundoplication, Bilroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator;
-
Subjects, in the opinion of the investigator, with profound nausea and/or vomiting at night;
-
Subjects, in the opinion of the investigator, with profound gastroparesis symptoms upon waking in the morning;
-
Subjects without a regular and defined sleep schedule;
-
Pregnancy, or subject that intends to become pregnant during participation in the study;
-
Chemical dependency;
-
Enterra lead impedance measurements ≥ 700 Ohms at screening visit;
-
Life expectancy < 1 year from conditions other than GI diseases;
-
Subjects with an underlying disease leading to follow-up by MRI;
-
Participation in other clinical studies;
-
Subjects involved in current or past medical-related litigation;
-
Subjects with cognitive impairment or other characteristic that would limit subject's ability to complete study requirements.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Louisville | Louisville | Kentucky | United States | 40202 |
Sponsors and Collaborators
- Enterra Medical, Inc.
Investigators
- Principal Investigator: Abigail Stocker, MD, University of Louisville
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CLN 001-PR-00755